Pancreatic Cancer Research

ResearcherUniversity of TriesteActive in the last 2 years

Alberto D’Angelo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8417-9172; OpenAlex author ID A5050977982. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 1 paper

Papers 9

  1. Recent Anti-KRAS G12D Therapies: A "Possible Impossibility" for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers17040704↗
  2. RNA-sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients. Co-author DOI 10.1002/cbin.11924↗
  3. Corrigendum to "Generation of murine tumour-reactive T cells by co-culturing murine pancreatic cancer organoids and peripheral blood lymphocytes". Co-author DOI 10.1016/j.bbrep.2022.101374↗
  4. Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine. Co-author DOI 10.1080/1120009x.2023.2190712↗
  5. Generation of murine tumour-reactive T cells by co-culturing murine pancreatic cancer organoids and peripheral blood lymphocytes. Co-author DOI 10.1016/j.bbrep.2022.101365↗
  6. Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-020-76465-9↗
  7. Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis o… Co-author DOI 10.1080/08830185.2020.1776274↗
  8. Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. Co-author DOI 10.2174/1568009620999200918122426↗
  9. Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0219566↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giandomenico Roviello · 5 shared papers, 2019–2023 · strength 0.61
  2. Stefan Bagby · 3 shared papers, 2019–2023 · strength 0.53
  3. Navid Sobhani · 2 shared papers, 2019–2025 · strength 0.46
  4. Masayuki Tokunaga · 2 shared papers, 2022–2023 · strength 0.44
  5. Monica Ramello · 3 shared papers, 2020–2023 · strength 0.40
  6. Roberto Petrioli · 3 shared papers, 2020–2023 · strength 0.40
  7. Martina Catalano · 3 shared papers, 2020–2023 · strength 0.40
  8. Giovanni Marchegiani · 1 shared paper, 2025 · strength 0.37
  9. Zahra Madjd · 2 shared papers, 2020–2023 · strength 0.31
  10. Enrico Mini · 2 shared papers, 2020 · strength 0.21
  11. Sima Kalantari · 1 shared paper, 2023 · strength 0.19
  12. Ashraf Mohamadkhani · 1 shared paper, 2023 · strength 0.19
  13. Akram Pourshams · 1 shared paper, 2023 · strength 0.19
  14. Maryam Sahlolbei · 1 shared paper, 2020 · strength 0.12
  15. Jafar Kiani · 1 shared paper, 2020 · strength 0.12
  16. Daniele Generali · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.